Constipation Information

By | December 8, 2014

PATIENT’INFORMATION’ ’ Last%Updated%9/24/2009% CONSTIPATION’ WHATCAUSESCONSTIPATION?% Tounderstandconstipation,ithelpstoknowhowthecolon(largeintestine)works.Asfoodmoves%

This leaflet has been written for parents and carers about how to use this medicine in children. Our information sometimes differs from that provided by the manufacturers, because their

8 Possible treatments Lubiprostone for chronic idiopathic constipation Lubiprostone is recommended as an option for treating chronic idiopathic constipation, that is,

Patient information from the BMJ Group Constipation in children Most children g et constipated fr om time to time . But if y our child has constipation

Celgene Corporation today announced that results were presented from multiple post-hoc analyses of its pivotal phase III FIRSTTM trial, comparing continuous REVLIMID® plus low-dose dexamethasone to a fixed duration of 18 cycles of Rd or 12 cycles of melphalan, prednisone and thalidomide for the treatment of newly diagnosed, transplant-ineligible multiple myeloma.

Drugs to Treat Constipation • Consumer Reports Best Buy Drugs• 3 This report compares the effectiveness, safety, and cost of medicines used

SELF CARE FORUM FACT SHEET NO. 5 (version 1.0.1) Produced by the Self Care Forum (selfcareforum.org). Last revised on 4 Mar 14. Please contact Libby

St Mark’s Hospital & Burdett Institute 2009 2 of 13 Constipation What is constipation? Constipation is a symptom (what a patient complains of) not a disease (what a

PACKAGE LEAFLET: INFORMATION FOR THE USER Constipation Relief Tablets (Bisacodyl) Read all of this leaflet carefully before you start taking this medicine:

Constipation Treatment A few important facts for all parents 1. Please keep your follow up appointment. It is natural to forget medications and

Page 2 What can be done to avoid constipation? Normal bowel movement habits are different for each person. How often you have bowel movements can vary from 3 stools a day to 3 stools a

People with neurological conditions such as Multiple Sclerosis, Parkinson’s Disease and Stroke are also more prone to constipation. This may be due to the effect of these

Constipation Why Am I Constipated? Constipation is passage of small amounts of hard, dry bowel movements, usually fewer than three times a week. (Chronic idiopathic constipation). University of California, Berkeley 2222 Bancroft Way

Strain caused by chronic constipation increases the risk of urinary incontinence in women by 140 to 370%. Constipation’s effects on the integrity of the bladder can be even worse in some cases. The connections between chronic constipation and urinary incontinence are

Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005;100 Suppl 1:S5–S22. 5. Irvine EJ, et al. Health-related quality of life in functional GI disorders: Focus on constipation and resource utilization.

FULL PRESCRIBING INFORMATION . 1 INDICATIONS AND USAGE. 1.1 Chronic Idiopathic Constipation . Amitiza® is indicated for the treatment of chronic idiopathic constipation in adults.

Celgene Corporation today announced that results were presented from multiple post-hoc analyses of its pivotal phase III FIRSTTM trial, comparing continuous REVLIMID® plus low-dose dexamethasone to a fixed duration of 18 cycles of Rd or 12 cycles of melphalan, prednisone and thalidomide for the treatment of newly diagnosed, transplant-ineligible multiple myeloma.

NEWTOWN, Pa. — Onconova Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data from

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited today announced four-year overall survival data from the ADCETRIS pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma .

Merck , known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA® , the company’s anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria , in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma whose disease